Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
1061-1080 of 1,782 trials

Crohn's and Colitis: Stopping Anti-TNF Treatment

We are studying if specific markers can help identify patients who can safely stop their anti-TNF treatment while in remission. This may help tailor treatment plans for better health outcomes.

Ulcerative ColitisCrohn's Disease>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Ventilator-Associated Pneumonia: Antimicrobial Stewardship Study

We are exploring a new method for managing antibiotics in patients with Ventilator-Associated Pneumonia in intensive care. This study aims to see if daily assessments can improve survival and reduce complications.

Ventilator Associated PneumoniaIntensive Care>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Acute Pyelonephritis: Short vs. Long Antibiotic Treatment

We are studying whether a 7-day antibiotic treatment is as effective as a 14-day treatment for kidney transplant recipients with acute pyelonephritis. This research aims to improve treatment options and patient safety.

Kidney Infection (Pyelonephritis)Kidney Transplant Recipients>2 yearsMonitoring phase (IV)Standard MedicinesInfectious DiseasesNephrologyUrology

Transfusion-Dependent β-Thalassemia: CTX001 Treatment

We are studying a new cell therapy for children with transfusion-dependent β-thalassemia to see if it can improve their condition and reduce the need for blood transfusions. The trial will also assess the safety of this treatment.

Transfusion-Dependent Thalassemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Telmisartan for Portal Hypertension in Liver Disease

We are studying whether telmisartan can lower liver pressure in patients with advanced chronic liver disease and portal hypertension. This trial will also assess its safety and impact on quality of life.

Compensated Advanced Chronic Liver DiseasePortal Hypertension3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteHepatologyInternal Medicine

Norfloxacin for Portal Hypertension in Decompensated Cirrhosis

We are studying whether norfloxacin can lower portal hypertension in patients with decompensated cirrhosis. The trial also looks at its effects on liver-related complications and overall patient well-being.

Portal HypertensionDecompensated Cirrhosis3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesGastroenterologyHepatology

Portosinusoidal Vascular Disorder: Edoxaban Study

We are studying the safety of edoxaban in patients with Portosinusoidal Vascular Disorder. The trial also explores its potential to prevent blood clots and improve quality of life.

Porto-Sinusoidal Vascular Disorder>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteCardiology

Rimegepant for Migraine: Effects on Obesity

We are studying how rimegepant affects migraine-related reactions in lean and obese individuals. The goal is to understand the relationship between body composition and migraine responses.

ObesityMigraine6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyNeurology

Skin Cancer Treatment: The BLESS Trial

We are investigating whether reducing the dose of bleomycin in electrochemotherapy can still effectively treat skin cancers. This study aims to see if patients can benefit from less medication while achieving similar tumor response.

Skin Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesDermatologyOncology

HIV-1 Treatment: High-Dose Antiretroviral Drugs

We are studying whether high doses of antiretroviral drugs can reduce the hidden HIV-1 reservoir in people living with HIV. This trial will also assess the safety and effects of the treatment on immune markers.

HIV Infection6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious Diseases

Behçet’s Disease Uveitis: Adalimumab vs. Tocilizumab

We are comparing two biologic treatments for severe uveitis in Behçet’s disease to see which one may better improve vision and reduce inflammation. This study will also evaluate the safety of both medications.

Severe Uveitis of Behçet’s Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOphthalmologyRheumatology

Breast Cancer: Palbociclib and Fulvestrant Combination

We are testing a combination of palbociclib and fulvestrant in women with advanced breast cancer who have not responded to prior treatments. The goal is to evaluate its effectiveness and safety for these patients.

Metastatic Breast CancerEfficacy phase (II)No PlaceboStandard MedicinesOncology

BRAF Mutated Melanoma: Encorafenib and Binimetinib with Cemiplimab and Fianlimab

We are studying a combination of treatments for patients with BRAF mutated melanoma and brain metastases. The goal is to see if this approach can help control the disease and improve survival.

Melanoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyOncology

Colorectal Cancer: PIPAC Treatment Study

We are testing a new chemotherapy method to prevent cancer spread in patients who have had surgery for high-risk colorectal cancer. This study will help us understand its effectiveness and impact on patients' quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Brigatinib for Pediatric and Young Adult ALK+ Cancer

We are studying the safety and effectiveness of brigatinib in children and young adults with ALK+ Anaplastic Large Cell Lymphoma and other solid tumors. This trial aims to find the best dose and understand how the drug works in these patients.

Anaplastic Large Cell Lymphoma (ALCL)Inflammatory Myofibroblastic Tumors (IMT)Other Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics

Type 2 Diabetes: Comparing Empagliflozin, Pioglitazone, and Semaglutide

We are studying how different diabetes medications affect fat tissue function in people with type 2 diabetes. This research may help us understand which drug works best for improving health outcomes.

Type 2 Diabetes6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteDiabetologyEndocrinology

Cardiovascular Disease Prevention: Personalized Statin Therapy

We are studying whether statin treatment guided by genetic risk can lower heart disease events in individuals at high risk. The trial will also look at how well patients accept this personalized approach and its effects on their health.

High Genetic Risk for Coronary Artery Disease1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Omalizumab Withdrawal in Severe Allergic Asthma

We are studying whether stopping Omalizumab after long-term treatment is as effective as continuing it for patients with well-controlled severe allergic asthma. This trial aims to assess asthma control and quality of life over time.

Allergic Asthma1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyPulmonology

Cortisone Treatment for Children with Facial Nerve Palsy

We are studying whether cortisone can help children with acute facial nerve paralysis recover better than a placebo. The trial will also look at safety and how the condition affects daily life.

Facial Nerve Palsy (Bell's Palsy)>2 yearsMonitoring phase (IV)Standard MedicinesNeurologyPediatrics

Oxytocin Treatment for Autism in Children

We are studying whether multiple doses of oxytocin can improve social symptoms in children with autism and intellectual disability. The trial also looks at other behavioral changes and stress-related measurements.

Autism Spectrum Disorder6-12 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemotePediatricsPsychiatry